Roivant Sciences (ROIV) surged 18.67% after reporting positive Phase 2 clinical trial results.
What changed — and why did investors react so strongly?
Here’s a quick breakdown of the catalyst behind ROIV’s move.
Source: Roivant Sciences / SEC EDGAR
For informational purposes only. Not financial advice.
#ROIV #Roivant #Biotech #Stocks #StockMarket
